GLAXF News and Press, GlaxoSmithKline Plc From 09/18/22

Summary The Zantac lawsuit will have minimal impact on Teva Pharmaceutical's financial position. At the end of August 2022, the company received approval in Europe for Ranivisio, which is a biosimilar of Lucentis, which is a medicine used to treat patients with certain. Teva P...

Summary I'm launching the first edition of the UK Top 40 High-Yield Blue-Chip Stocks list. The list is based on stocks from the FTSE 100 and FTSE 250. Given the weak economic backdrop, it shouldn't be a complete surprise that the average dividend yield across this list of stoc...

GSK plc (GSK) Citi's 17th Annual BioPharma Conference September 7, 2022, 01:50 PM ET Company Participants Roger Connor - President, Global Vaccines & Global Health Phil Dormitzer - Senior Vice President, Head of Vaccines R&D Conference Call Participants...

Summary A little over a year ago is our last coverage on GSK. We looked at implied split in value between GSK's biopharma division and the consumer division, now called Haleon, when it was supposed to split off. Haleon seems to be valued fully, but the implied value based on p...

Summary Tweedy, Browne’s 13F portfolio value decreased from $3.10B to $2.45B this quarter. They added FedEx Corp., American Express, and Paramount Global while decreasing AutoZone and dropping 3M. Alphabet at ~18% of the portfolio is the largest position. This...

The superior reactogenicity profile of Novavax's Nuvaxovid vaccine could make it the preferred choice amongst some in an endemic COVID environment. The company's other promising vaccine, NanoFlu, is being overlooked due to the market's focus on COVID. The recent decline in the NVA...

GSK was having a turnaround year, with drugs pipeline strong and H1 results impressive. Zantac lawsuits are presenting a significant risk to investing in GSK. Haleon's public offering was underwhelming. A few weeks ago, GSK’s ( OTCPK:GLAXF , [[GSK]]) CEO, Emma...

GSK plc (GLAXF) Q2 2022 Earnings Conference Call July 27, 2022, 07:00 ET Company Participants Nick Stone - IR Emma Walmsley - CEO & Director Hal Barron - Chief Scientific Officer, President of R&D and Director Luke Miels - Chief Commercial Officer ...

The following slide deck was published by GSK plc in conjunction with their 2022 Q2 earnings call. For further details see: GSK plc 2022 Q2 - Results - Earnings Call Presentation

Pfizer has a pipeline with more than 90 drugs in development. Pfizer is developing two drugs capable of generating more than a billion sales. Competition is fierce but Pfizer is in the race. Pfizer's story of success Pharmaceutical giant Pfizer ( PFE ) is one of ...